Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7696586 | 0.92 | HTT (0.48) | SIGMAR1HTTALDH1A1 | |
| SCHEMBL30191225 | 0.83 | PIN1 (0.54) | PIN1MTNR1AMTNR1BHTTDRD2 | |
| SCHEMBL11305795 | 0.83 | PIN1 (0.54) | PIN1MTNR1AMTNR1BHTTDRD2 | |
| SCHEMBL599522 | 0.81 | GAA (0.47) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL29458278 | 0.81 | GAA (0.47) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL608005 | 0.81 | GAA (0.47) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL30721195 | 0.81 | GAA (0.47) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL11666042 | 0.80 | PIN1 (0.51) | PIN1MTNR1AMTNR1BHTR2CSLC6A3 | |
| SCHEMBL11354503 | 0.77 | HTR2C (0.45) | HTR2CSLC6A3ABL1RIN1ALDH1A1 | |
| SCHEMBL30420872 | 0.77 | PIN1 (0.46) | PIN1MTNR1AMTNR1BSIGMAR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150037891-A1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | SAPHIRE ANDREW (US) | 2015-02-05 | — | — | US | disclosed |
| US-8802439-B2 | Methods for enhancing infectivity of retroviruses | NATIONAL INSTITUTES OF HEALTH | 2014-08-12 | — | — | US | disclosed |
| EP-2733213-A1 | Kit for producing a retrovirus with enhanced infectivity | Saphire, Andrew C. (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2432885-B1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | SAPHIRE ANDREW C (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2432885-A2 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | The Scripps Research Institute (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120064604-A1 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | NATIONAL INSTITUTES OF HEALTH | 2012-03-15 | — | — | US | disclosed |
| WO-2010134975-A2 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7786090-B2 | Methods and compositions for treating and preventing neurologic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-31 | — | — | US | disclosed |
| US-20070282017-A1 | Methods and compositions for treating and preventing neurologic disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282017-A1 | Methods and compositions for treating and preventing neurologic disorders | ACHE, NLN, AQP4 | PIN1 1865/4885MTNR1A 258/4885MTNR1B 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.